News & Events
Cantor Virtual Global Healthcare Conference: Crinetics Pharmaceuticals, Inc.
Event Date: September 15, 2020
READ MORESeptember 14, 2020 10:30 AM EDT : 22nd Annual H.C. Wainwright Global Investment Conference
Event Date: September 14, 2020
READ MORESeptember 9, 2020 12:50 PM EDT : Baird Global Healthcare Conference
Event Date: September 9, 2020
READ MORENew Data from Paltusotine and ACTH Antagonist Development Programs- European Congress of Endocrinology
A presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at...
READ MORECrinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) appointments Camille L. Bedrosian, M.D. as an independent member of its board of directors.
READ MORECrinetics Pharmaceuticals to Participate in September Investor Conferences
Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and...
READ MORECrinetics Pharmaceuticals ACROBAT Edge Phase 2 Interim Results and Corporate Update Conference Call
Event Date: April 7, 2020
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced financial results for the second quarter ended June 30, 2020 and provided a...
READ MOREFDA Grants Crinetics Pharmaceuticals (CRNX) Orphan Drug Designation – Paltusotine for the Treatment of Acromegaly
The orphan drug designation by the FDA for paltusotine to treat acromegaly validates the encouraging clinical data we have seen...
READ MORECrinetics Confirms Completion – Half of Enrolled Patients in Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.